Severe mental illness (SMI) encompasses conditions that profoundly disrupt cognition, perception, mood, and functioning, requiring sustained specialist intervention. The term typically includes schizophrenia, bipolar disorder, and severe treatment-resistant depression, though this lesson focuses primarily on the psychotic and mood spectrum disorders. A 28-year-old man presenting with persecutory delusions, auditory hallucinations, and social withdrawal exemplifies the diagnostic challenge: distinguishing first-episode psychosis requires careful exclusion of organic causes, substance-induced states, and affective psychosis. Understanding SMI epidemiology and classification is essential for early intervention, which significantly improves long-term outcomes.
Core Definitions and Classification:
Severe Mental Illness (SMI): Mental disorder causing substantial functional impairment in major life activities, typically requiring secondary care involvement for ≥2 years
Schizophrenia : Chronic psychotic disorder characterized by positive symptoms (hallucinations, delusions), negative symptoms (avolition, blunted affect), and cognitive impairment
Bipolar Disorder : Episodic mood disorder with manic/hypomanic episodes, often alternating with depressive episodes
| Condition | Prevalence | Peak Onset (years) | Male:Female Ratio | Psychotic Features |
|---|---|---|---|---|
| Schizophrenia | 0.7-1.0% | 18-35 (bimodal) | 1.4:1 | Core feature (100%) |
| Bipolar I | 0.6% | 15-25 | 1:1 | 50-70% during mania |
| Bipolar II | 0.4% | 20-30 | 1:1.5 (F>M) | Rare (5-10%) |
📌 Mnemonic for SMI Core Features: SPICE - Severity (functional impairment), Persistence (chronicity), Impairment (occupational/social), Complexity (multidomain), Engagement (specialist services required)
Epidemiological Risk Factors:
Schizophrenia risk factors:
Bipolar disorder risk factors:

The neurobiological substrate of severe mental illness involves dysregulation across multiple neurotransmitter systems, particularly dopamine, glutamate, and serotonin pathways. In schizophrenia , the dopamine hypothesis posits mesolimbic hyperactivity (producing positive symptoms) alongside mesocortical hypoactivity (contributing to negative symptoms and cognitive deficits). Bipolar disorder involves dysregulation of monoaminergic systems, circadian rhythm disruption, and altered neuroplasticity. These mechanisms explain symptom clusters, guide pharmacological targeting, and clarify why treatment responses differ across symptom domains.
Schizophrenia Neurobiology:
Dopamine pathways:
NMDA receptor hypofunction: Glutamate deficiency model explains cognitive impairment and negative symptoms
Structural changes:
Bipolar Disorder Neurobiology:
Monoamine dysregulation:
Circadian rhythm disruption:
Symptom Cluster Architecture:
| Domain | Schizophrenia Examples | Bipolar Mania Examples | Neurobiological Basis |
|---|---|---|---|
| Positive | Auditory hallucinations, persecutory delusions | Grandiose delusions, mood-congruent hallucinations | Mesolimbic dopamine excess |
| Negative | Avolition, alogia, anhedonia | (Not applicable) | Mesocortical dopamine deficit |
| Cognitive | Working memory, executive function deficits | Distractibility, poor judgment | Prefrontal cortex dysfunction |
| Mood | Depression (25% comorbid), blunted affect | Euphoria, irritability, lability | Monoamine dysregulation |
A 32-year-old woman presents with three weeks of reduced sleep (3 hours/night), pressured speech, excessive spending (£15,000 on credit cards), and grandiose beliefs about starting a tech company despite no relevant experience. She has no psychiatric history but her mother has bipolar disorder. Distinguishing manic episode from substance-induced mania, schizophrenia with affective symptoms, or personality-driven impulsivity requires systematic application of diagnostic criteria. NICE CG178 (psychosis and schizophrenia) and NICE CG185 (bipolar disorder) emphasize early recognition, comprehensive assessment, and prompt initiation of evidence-based treatment.
Schizophrenia Diagnostic Criteria (ICD-11):
Minimum duration: Symptoms present for ≥1 month
Core symptoms (≥2 required):
Exclusion criteria:
Bipolar Disorder Diagnostic Criteria (DSM-5):
Manic Episode (Bipolar I):
Hypomanic Episode (Bipolar II):
📌 Mnemonic for Mania: DIGFAST - Distractibility, Indiscretion (excessive involvement in pleasurable activities), Grandiosity, Flight of ideas, Activity increase, Sleep deficit (decreased need), Talkativeness (pressured speech)
Essential Investigations:
Baseline screening (all first-episode psychosis/mania):
Extended screen if atypical features:

Distinguishing schizophrenia from schizoaffective disorder, bipolar disorder with psychotic features, and substance-induced psychosis represents a common clinical challenge. Temporal relationships between mood and psychotic symptoms are critical: in schizoaffective disorder, psychosis persists for ≥2 weeks in the absence of mood symptoms, whereas in bipolar disorder with psychotic features, psychosis occurs only during mood episodes. Diagnostic stability is poor in early illness-up to 25% of first-episode psychosis diagnoses change over 3 years as longitudinal patterns emerge.
Key Diagnostic Discriminators:
| Feature | Schizophrenia | Bipolar I with Psychosis | Schizoaffective Disorder |
|---|---|---|---|
| Mood episodes | Absent or brief relative to psychosis | Prominent, define episodes | Prominent but psychosis persists independently ≥2 weeks |
| Psychotic symptoms outside mood episodes | Present (core feature) | Absent | Present (≥2 weeks without mood symptoms) |
| Negative symptoms | Prominent, persistent | Absent or only during depression | Variable |
| Functional trajectory | Progressive decline common | Episodic with inter-episode recovery | Intermediate between schizophrenia and bipolar |
| Family history | Schizophrenia > bipolar | Bipolar > schizophrenia | Both conditions increased |
Substance-Induced Psychosis:
Cannabis-induced psychosis:
Stimulant-induced psychosis (amphetamines, cocaine):
Organic Psychosis Red Flags:
🚩 Red Flag: New-onset psychosis in patient >40 years requires urgent neuroimaging and comprehensive organic screen-likelihood of structural/metabolic cause approaches 20-25% in this age group.
NICE CG178 recommends offering oral antipsychotic medication to all individuals with first-episode psychosis, combined with family intervention and individual CBT for psychosis. Treatment goals differ between schizophrenia -focused on symptom reduction and relapse prevention-and bipolar disorder -emphasizing mood stabilization and preventing episode recurrence. The choice between typical and atypical antipsychotics balances efficacy against side-effect profiles, with monitoring requirements varying by agent.
Schizophrenia Pharmacological Management:
First-line antipsychotics (NICE CG178):
Specific dosing examples:
Treatment-resistant schizophrenia:
Bipolar Disorder Acute and Maintenance Treatment:
Acute mania (NICE CG185):
Maintenance treatment:
| Antipsychotic | Starting Dose | Target Dose | Key Monitoring | Notable Side Effects |
|---|---|---|---|---|
| Risperidone | 2mg daily | 4-6mg daily | Prolactin, EPSE | Hyperprolactinemia (60%), EPSE |
| Olanzapine | 5-10mg daily | 10-20mg daily | Weight, glucose, lipids | Weight gain (+5kg in 40%), metabolic syndrome |
| Aripiprazole | 10-15mg daily | 10-30mg daily | Akathisia | Akathisia (25%), activation |
| Clozapine | 12.5mg daily | 300-450mg daily | FBC weekly→monthly, ECG | Neutropenia (0.8%), myocarditis (rare), hypersalivation |
Real-world management requires integrating pharmacotherapy with psychosocial interventions, addressing comorbidities, and adapting treatment for special populations. Approximately 50% of individuals with schizophrenia have comorbid substance use disorder, and 40-60% of those with bipolar disorder experience anxiety disorders. Pregnancy, elderly patients, and treatment-resistant cases demand modified approaches balancing efficacy against safety. Recovery-oriented care emphasizes functional outcomes beyond symptom reduction, with early intervention services demonstrating 20-30% reduction in relapse rates compared to standard care.
Pregnancy and Perinatal Management:
Schizophrenia in pregnancy:
Bipolar disorder in pregnancy:
Elderly Patients:
Treatment-Resistant and Complex Cases:
Clozapine augmentation strategies (after adequate clozapine trial to 900mg):
Rapid cycling bipolar disorder (≥4 episodes/year):
⭐ Clinical Pearl: In treatment-resistant cases, verify adherence (plasma drug levels), optimize dose, ensure adequate trial duration (6-8 weeks), and exclude substance use before labeling as treatment-resistant. Up to 40% of apparent resistance reflects non-adherence or inadequate dosing.
Key Take-Aways:
Essential Severe Mental Illness Numbers:
| Parameter | Value | Clinical Significance |
|---|---|---|
| Schizophrenia lifetime prevalence | 0.7-1.0% | ~1 in 100 population |
| Bipolar disorder lifetime prevalence | 1-2% | Bipolar I 0.6%, Bipolar II 0.4% |
| First-degree relative risk (schizophrenia) | 10× baseline | Strongest risk factor |
| Cannabis-induced psychosis transition rate | 25-30% | High conversion to primary disorder |
| Treatment-resistant schizophrenia | 30% of cases | Requires clozapine consideration |
| Lithium therapeutic range | 0.6-1.0 mmol/L | Narrow therapeutic window |
| Clozapine neutropenia risk | 0.8% | Mandates weekly FBC initially |
| Relapse rate if antipsychotic stopped | 50-60% within 6 months | Justifies maintenance treatment |
Key Principles/Pearls:
Quick Reference:
| Clinical Scenario | Action | Key Numbers |
|---|---|---|
| First-episode psychosis | Oral atypical antipsychotic + CBT + family intervention | Response expected 2-4 weeks |
| Acute mania | Antipsychotic (olanzapine 15-20mg) or valproate (load 20-30mg/kg) | Reassess at 3-7 days |
| Treatment-resistant schizophrenia | Clozapine 12.5mg→300-450mg, weekly FBC×18 weeks | After 2 failed trials (6-8 weeks each) |
| Bipolar maintenance | Lithium 400mg→target level 0.6-1.0 mmol/L | Check level weekly→3-monthly |
| Suspected substance-induced psychosis | Urine toxicology, observe 1 month abstinence | If persists >1 month, likely primary disorder |
Test your understanding with these related questions
A 30-year-old woman presents with episodes of feeling detached from herself and her surroundings, as if watching herself from outside her body. These episodes last 10-15 minutes and cause significant distress. What is the most likely diagnosis?
Get full access to all lessons, practice questions, and more.
Start Your Free Trial